stockportfolio.pro
Baxter International Inc. (BAX)
Healthcare · Medical Instruments & Supplies · NYSE
Baxter International Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.16B | $10.58B | $11.10B | $11.36B | $11.67B | $12.15B | $15.11B | $14.81B | $10.64B | $11.24B |
| Gross profit | $4.12B | $4.47B | $4.76B | $4.76B | $4.59B | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B |
| Net income | $4.96B | $602.00M | $1.55B | $1.00B | $1.10B | $1.28B | $-2.43B | $2.66B | $-649.00M | $-957.00M |
| Net margin | 48.9% | 5.7% | 13.9% | 8.8% | 9.4% | 10.6% | -16.1% | 17.9% | -6.1% | -8.5% |
Source: Baxter International Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into BAX stock?
At today's market cap of $10.34B, Baxter International Inc. is priced for free-cash-flow growth of about 13.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $332.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -22.1%/yr over the last five fiscal years and revenue -0.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Baxter International Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BAX in your portfolio →
Baxter International Inc. financial history by metric
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Baxter International Inc. — frequently asked questions
What is Baxter International Inc.'s revenue?
Baxter International Inc. (BAX) reported revenue of $11.24B for fiscal year 2025, up 5.7% from the prior year, according to its SEC filings.
Is Baxter International Inc. profitable?
No — BAX reported a net loss of $-957.00M in fiscal 2025.
What is BAX's P/E ratio?
Baxter International Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Baxter International Inc. growing?
BAX's revenue grew at roughly -0.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Baxter International Inc. have?
As of fiscal year 2025, BAX carried roughly $9.44B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Baxter International Inc.'s gross margin?
BAX's gross margin was 30.1% in fiscal 2025 — gross profit of $3.38B on revenue of $11.24B.
What is Baxter International Inc.'s market cap?
Baxter International Inc. (BAX) has a market capitalization of about $10.34B, based on the latest data in our nightly-refreshed cache.
When does Baxter International Inc.'s fiscal year end?
BAX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BAX stock?
At today's market cap of $10.34B, Baxter International Inc. is priced for free-cash-flow growth of about 13.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $332.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -22.1%/yr over the last five fiscal years and revenue -0.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Baxter International Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.